1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Introduction
2.2. Define: Research Objective
2.3. Determine: Research Design
2.4. Prepare: Research Instrument
2.5. Collect: Data Source
2.6. Analyze: Data Interpretation
2.7. Formulate: Data Verification
2.8. Publish: Research Report
2.9. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer patients worldwide
5.1.1.2. Increasing adoption of advanced cancer therapeutics
5.1.1.3. Surging investments in research and development activities of cancer treatment
5.1.2. Restraints
5.1.2.1. Capital intensive treatment and procedures
5.1.3. Opportunities
5.1.3.1. Extensive development of bioinformatics tools in drug development process
5.1.3.2. Growing number of clinical trials for cancer immunotherapy
5.1.4. Challenges
5.1.4.1. Complications in cancer limiting the immune response
5.2. Cumulative Impact of COVID-19

6. Cancer Immunotherapy Market, by Function
6.1. Introduction
6.2. Breast Cancer
6.3. Colorectal Cancer
6.4. Head & Neck Cancer
6.5. Lung Cancer
6.6. Melanoma
6.7. Multiple Myeloma
6.8. Prostate Cancer

7. Cancer Immunotherapy Market, by Product
7.1. Introduction
7.2. Cell Therapies
7.2.1. Chimeric Antigen Receptor T Cell Therapy
7.2.2. Dendritic Cells
7.3. Checkpoint Inhibitors
7.3.1. Cytotoxic T-Lymphocyte-Associated Protein-4
7.3.2. Programmed Death 1 & Programmed Death Ligand 1
7.4. Immunomodulators
7.4.1. Granulocyte-Macrophage Colony-Stimulating Factor
7.4.2. Interferons
7.4.3. Interleukins
7.4.4. Oncolytic Virus
7.5. Monoclonal Antibodies
7.5.1. Bispecific Monoclonal Antibodies
7.5.2. Conjugated Monoclonal Antibodies
7.5.3. Naked Monoclonal Antibodies
7.6. Vaccines
7.6.1. Prophylactic Vaccines
7.6.2. Therapeutic Vaccines

8. Cancer Immunotherapy Market, by End User
8.1. Introduction
8.2. Cancer Research Institutes
8.3. Clinics
8.4. Hospitals

9. Americas Cancer Immunotherapy Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Cancer Immunotherapy Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand

11. Europe, Middle East & Africa Cancer Immunotherapy Market
11.1. Introduction
11.2. France
11.3. Germany
11.4. Italy
11.5. Netherlands
11.6. Qatar
11.7. Russia
11.8. Saudi Arabia
11.9. South Africa
11.10. Spain
11.11. United Arab Emirates
11.12. United Kingdom

12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion

13. Company Usability Profiles
13.1. Amgen Inc.
13.2. Amneal Pharmaceutical Inc.
13.3. Apotex Inc
13.4. Astrazeneca
13.5. Avid Bioservices, Inc.
13.6. Bausch Health Companies Inc.
13.7. Bayer AG
13.8. Bristol-Myers Squibb
13.9. C.H. Boehringer Sohn AG & Ko. KG
13.10. Celgene Corporation
13.11. Dr. Reddy's Laboratories Ltd
13.12. ELI Lilly and Company
13.13. F. Hoffmann-La Roche Ltd
13.14. Fresenius Kabi AG
13.15. GlaxoSmithKline Plc
13.16. Gristone Oncology, Inc.
13.17. Hikma Pharmaceutical PLC
13.18. Immunomedics Inc
13.19. Janssen Global Services, LLC
13.20. Lupin Limited
13.21. Merck & Co., Inc.
13.22. Mylan N.V.
13.23. Novartis International AG
13.24. OSE Immunotherapeutics SA
13.25. Pfizer, Inc.
13.26. Seagen Inc
13.27. Spectrum Pharmaceuticals, Inc.
13.28. Sun Pharmaceutical Industries Ltd
13.29. Teva Pharmaceutical Industries Ltd

14. Appendix
14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER IMMUNOTHERAPY MARKET: MARKET DYNAMICS
FIGURE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2020 VS 2027 (%)
FIGURE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2020 VS 2027 (USD BILLION)
FIGURE 5. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2027
FIGURE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, 2018-2027 (USD BILLION)
FIGURE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, 2018-2027 (USD BILLION)
FIGURE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, 2018-2027 (USD BILLION)
FIGURE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, 2018-2027 (USD BILLION)
FIGURE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, 2018-2027 (USD BILLION)
FIGURE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2027 (USD BILLION)
FIGURE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, 2018-2027 (USD BILLION)
FIGURE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2020 VS 2027 (%)
FIGURE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2020 VS 2027 (USD BILLION)
FIGURE 22. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2027
FIGURE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, 2018-2027 (USD BILLION)
FIGURE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, 2018-2027 (USD BILLION)
FIGURE 26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELLS, 2018-2027 (USD BILLION)
FIGURE 28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, 2018-2027 (USD BILLION)
FIGURE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 31. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4, 2018-2027 (USD BILLION)
FIGURE 32. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 33. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROGRAMMED DEATH 1 & PROGRAMMED DEATH LIGAND 1, 2018-2027 (USD BILLION)
FIGURE 34. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROGRAMMED DEATH 1 & PROGRAMMED DEATH LIGAND 1, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 35. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, 2018-2027 (USD BILLION)
FIGURE 36. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 37. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, 2018-2027 (USD BILLION)
FIGURE 38. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 39. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERFERONS, 2018-2027 (USD BILLION)
FIGURE 40. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERFERONS, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 41. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERLEUKINS, 2018-2027 (USD BILLION)
FIGURE 42. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERLEUKINS, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 43. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS, 2018-2027 (USD BILLION)
FIGURE 44. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 45. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2027 (USD BILLION)
FIGURE 46. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 47. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC MONOCLONAL ANTIBODIES, 2018-2027 (USD BILLION)
FIGURE 48. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC MONOCLONAL ANTIBODIES, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 49. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, 2018-2027 (USD BILLION)
FIGURE 50. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 51. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, 2018-2027 (USD BILLION)
FIGURE 52. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 53. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, 2018-2027 (USD BILLION)
FIGURE 54. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 55. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROPHYLACTIC VACCINES, 2018-2027 (USD BILLION)
FIGURE 56. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 57. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPEUTIC VACCINES, 2018-2027 (USD BILLION)
FIGURE 58. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 59. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2020 VS 2027 (%)
FIGURE 60. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2020 VS 2027 (USD BILLION)
FIGURE 61. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2027
FIGURE 62. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, 2018-2027 (USD BILLION)
FIGURE 63. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 64. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CLINICS, 2018-2027 (USD BILLION)
FIGURE 65. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CLINICS, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 66. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, 2018-2027 (USD BILLION)
FIGURE 67. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2020 VS 2027 (USD BILLION)
FIGURE 68. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 69. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 70. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 71. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 72. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 73. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 74. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 75. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 76. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 77. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 78. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 79. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 80. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 81. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 82. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 83. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 84. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 85. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 86. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 87. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 88. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 89. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 90. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 91. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 92. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 93. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 94. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 95. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 96. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 97. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
FIGURE 98. GLOBAL CANCER IMMUNOTHERAPY MARKET: FPNV POSITIONING MATRIX
FIGURE 99. GLOBAL CANCER IMMUNOTHERAPY MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 100. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CANCER IMMUNOTHERAPY MARKET, BY TYPE

List of Tables

TABLE 1. GLOBAL CANCER IMMUNOTHERAPY MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016-2020
TABLE 3. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY FUNCTION, 2018-2027 (USD BILLION)
TABLE 4. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2027 (USD BILLION)
TABLE 5. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2027 (USD BILLION)
TABLE 6. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HEAD & NECK CANCER, BY REGION, 2018-2027 (USD BILLION)
TABLE 7. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2027 (USD BILLION)
TABLE 8. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2027 (USD BILLION)
TABLE 9. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2027 (USD BILLION)
TABLE 10. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2027 (USD BILLION)
TABLE 11. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PRODUCT, 2018-2027 (USD BILLION)
TABLE 12. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CELL THERAPIES, BY REGION, 2018-2027 (USD BILLION)
TABLE 13. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY, BY REGION, 2018-2027 (USD BILLION)
TABLE 14. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY DENDRITIC CELLS, BY REGION, 2018-2027 (USD BILLION)
TABLE 15. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2027 (USD BILLION)
TABLE 16. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4, BY REGION, 2018-2027 (USD BILLION)
TABLE 17. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROGRAMMED DEATH 1 & PROGRAMMED DEATH LIGAND 1, BY REGION, 2018-2027 (USD BILLION)
TABLE 18. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2027 (USD BILLION)
TABLE 19. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR, BY REGION, 2018-2027 (USD BILLION)
TABLE 20. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2027 (USD BILLION)
TABLE 21. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY INTERLEUKINS, BY REGION, 2018-2027 (USD BILLION)
TABLE 22. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS, BY REGION, 2018-2027 (USD BILLION)
TABLE 23. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2027 (USD BILLION)
TABLE 24. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC MONOCLONAL ANTIBODIES, BY REGION, 2018-2027 (USD BILLION)
TABLE 25. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CONJUGATED MONOCLONAL ANTIBODIES, BY REGION, 2018-2027 (USD BILLION)
TABLE 26. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY NAKED MONOCLONAL ANTIBODIES, BY REGION, 2018-2027 (USD BILLION)
TABLE 27. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY VACCINES, BY REGION, 2018-2027 (USD BILLION)
TABLE 28. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2027 (USD BILLION)
TABLE 29. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2027 (USD BILLION)
TABLE 30. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY END USER, 2018-2027 (USD BILLION)
TABLE 31. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2027 (USD BILLION)
TABLE 32. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY CLINICS, BY REGION, 2018-2027 (USD BILLION)
TABLE 33. GLOBAL CANCER IMMUNOTHERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2027 (USD BILLION)
TABLE 34. AMERICAS CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 35. ARGENTINA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 36. BRAZIL CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 37. CANADA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 38. MEXICO CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 39. UNITED STATES CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 40. ASIA-PACIFIC CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 41. AUSTRALIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 42. CHINA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 43. INDIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 44. INDONESIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 45. JAPAN CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 46. MALAYSIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 47. PHILIPPINES CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 48. SINGAPORE CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 49. SOUTH KOREA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 50. TAIWAN CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 51. THAILAND CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 52. EUROPE, MIDDLE EAST & AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 53. FRANCE CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 54. GERMANY CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 55. ITALY CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 56. NETHERLANDS CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 57. QATAR CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 58. RUSSIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 59. SAUDI ARABIA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 60. SOUTH AFRICA CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 61. SPAIN CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 62. UNITED ARAB EMIRATES CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 63. UNITED KINGDOM CANCER IMMUNOTHERAPY MARKET SIZE, 2018-2027 (USD BILLION)
TABLE 64. GLOBAL CANCER IMMUNOTHERAPY MARKET: SCORES
TABLE 65. GLOBAL CANCER IMMUNOTHERAPY MARKET: BUSINESS STRATEGY
TABLE 66. GLOBAL CANCER IMMUNOTHERAPY MARKET: PRODUCT SATISFACTION
TABLE 67. GLOBAL CANCER IMMUNOTHERAPY MARKET: RANKING
TABLE 68. GLOBAL CANCER IMMUNOTHERAPY MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 69. GLOBAL CANCER IMMUNOTHERAPY MARKET: MERGER & ACQUISITION
TABLE 70. GLOBAL CANCER IMMUNOTHERAPY MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 71. GLOBAL CANCER IMMUNOTHERAPY MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 72. GLOBAL CANCER IMMUNOTHERAPY MARKET: INVESTMENT & FUNDING
TABLE 73. GLOBAL CANCER IMMUNOTHERAPY MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 74. GLOBAL CANCER IMMUNOTHERAPY MARKET: LICENSE & PRICING

Companies Mentioned

Amgen Inc.
Amneal Pharmaceutical Inc.
Apotex Inc
Astrazeneca
Avid Bioservices, Inc.
Bausch Health Companies Inc.
Bayer AG
Bristol-Myers Squibb
C.H. Boehringer Sohn AG & Ko. KG
Celgene Corporation
Dr. Reddy's Laboratories Ltd
ELI Lilly and Company
F. Hoffmann-La Roche Ltd
Fresenius Kabi AG
GlaxoSmithKline Plc
Gristone Oncology, Inc.
Hikma Pharmaceutical PLC
Immunomedics Inc
Janssen Global Services, LLC
Lupin Limited
Merck & Co., Inc.
Mylan N.V.
Novartis International AG
OSE Immunotherapeutics SA
Pfizer, Inc.
Seagen Inc
Spectrum Pharmaceuticals, Inc.
Sun Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd